#United States #Orlando #Qnovia #Respiratory Innovation #ATS Summit

Overview

Qnovia, a clinical-stage pharmaceutical and medtech company, has recently announced an important milestone in its journey to innovate nicotine cessation methods. The company has been selected to present at the prestigious 2026 Respiratory Innovation Summit (RIS), which is organized by the American Thoracic Society (ATS). This significant event will take place from May 15-16, 2026, in Orlando, Florida, bringing together top leaders and innovators in the field of pulmonary health.

Participation Details

Qnovia's selection for this event was not random; it came from a highly competitive pool of applicants. The company will partake in the summit's oral showcase, a coveted opportunity that allows a select group of companies to present their newest research findings to an audience comprised of clinicians, researchers, and industry leaders dedicated to enhancing respiratory care. Beyond its oral presentation, Qnovia will also contribute a poster to the event, underscoring its innovative approach and relentless pursuit of advanced solutions for nicotine addiction.

Statements from Leadership

Mario Danek, the CEO of Qnovia, highlighted the importance of shifting the focus from merely treating the disorders caused by smoking to addressing nicotine dependence proactively. In his words, "For decades, much of the focus has been on treating the downstream consequences of smoking, often when disease is already advanced." He emphasized that the landscape of nicotine consumption has evolved, creating an opportunity for restructured cessation strategies to align better with current dependence patterns.

Significance of the Summit

The Respiratory Innovation Summit is a significant occasion taking place alongside the ATS's annual international conference. This dual event features emerging technologies and therapeutic strategies aimed at improving outcomes for individuals suffering from respiratory diseases. The summit is expected to attract over 400 prominent figures from various sectors within the respiratory ecosystem, including innovators, investors, and healthcare practitioners.

Evolving Cessation Strategies

Qnovia’s participation at the summit is not just a reflection of its innovative prowess but also a representation of the changing landscape around nicotine use and cessation. The company is at the forefront of developing new nicotine cessation strategies that take into account pharmacokinetic delivery systems and the behavioral aspects associated with nicotine dependence. Recently, Qnovia completed a Phase 1 clinical study in the United States, a significant step towards bolstering its development objectives and showcasing its innovative capabilities.

About Qnovia

Founded in 2018 by Mario Danek, Qnovia aims to revolutionize the way nicotine dependence is treated with its cutting-edge drug delivery platform, the RespiRx™. This technology is recognized as the first cartridge-based, ultra-portable vibrating mesh nebulizer and presents a remarkable opportunity to enhance treatment processes for various health conditions. Qnovia looks to leverage its unique inhalation delivery technologies to better serve patients and improve health outcomes across numerous indications.

For additional information about their developments and innovations, you can visit Qnovia's official site.